Adenovirus F protein as a delivery vehicle for botulinum B

BMC Immunology

Volumn 11, Issue , 2010, Pages

  Clapp, Beata ^a   Golden, Sarah ^a   Maddaloni, Massimo ^a   Staats, Herman F ^b   Pascual, David W ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS 2 FIBER PROTEIN; ANTIGEN; BOTULINUM TOXIN B; CHOLERA TOXIN; DRUG VEHICLE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; UNCLASSIFIED DRUG; BOTULINUM TOXIN; CYTOKINE; HYBRID PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HYPOTHESIS; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; LD 50; MOUSE; NONHUMAN; SERODIAGNOSIS; SEROTYPE; TH1 CELL; TH2 CELL; ADENOVIRUS; ANIMAL; B LYMPHOCYTE; BOTULISM; C57BL MOUSE; CHEMISTRY; HELPER CELL; IMMUNOASSAY; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PROTEIN TERTIARY STRUCTURE; SURVIVAL; VACCINATION;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; B-LYMPHOCYTES; BOTULINUM TOXINS; BOTULISM; CHOLERA TOXIN; CYTOKINES; IMMUNOASSAY; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION; VIRAL PROTEINS;

EID: 77954285159     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-36     Document Type: Article

References (42)

1. Hatheway CL. Toxigenic clostridia. Clin Microbiol Rev 1990, 3:66-98. 358141, 2404569.
2. Hatheway C. Clostridium botulinum. Infectious Diseases 1991, 583-1586. Orlando: WB Saunders, Bartlett JG, Blacklow NR.
3. Villar RG, Elliott SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin N Am 2006, 20:313-327.
4. Shukla HD, Sharma SK. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol 2005, 31:11-18. 10.1080/10408410590912952, 15839401.
5. Taylor A. Botulism and its control. Am J Nursing 1973, 73:1380-1382.
6. Horowitz B. Botulinum Toxin. Crit Care Clin 2005, 21:825-839. 10.1016/j.ccc.2005.06.008, 16168317.
7. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. Botulism toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070. 10.1001/jama.285.8.1059, 11209178.
8. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiological review. Ann Intern Med 1998, 129:221-228.
9. Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 2007, 27:303-318.
10. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966. 10.1016/S0300-9084(00)01173-1, 11086225.
11. Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1988, 66:4817-4822.
12. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008, 76:1314-1318. 10.1128/IAI.01025-07, 2258812, 18070903.
13. Clayton J, Middlebrook JL. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000, 18:1855-1862. 10.1016/S0264-410X(99)00253-4, 10699334.
14. Yu Y-Z, Zhang S-M, Sun Z-W, Wang S, Yu W-Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 2007, 25:8843-8850. 10.1016/j.vaccine.2007.10.016, 18022294.
15. Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxin. Mol Microbiol 1994, 13:1-8. 10.1111/j.1365-2958.1994.tb00396.x, 7527117.
16. Zhou L, de Paiva A, Liu D, Aoki R, Dolly JO. Expression and purification of the light chain of botulinum neurotoxin A: A single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after reconstitution with the heavy chain. Biochemistry 1995, 34:1517-1518.
17. Smith LA. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 1998, 36:1539-1548. 10.1016/S0041-0101(98)00146-9, 9792170.
18. Park J-B, Simpson LL. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 2003, 71:1147-1154. 10.1128/IAI.71.3.1147-1154.2003, 148837, 12595426.
19. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struc Biol 1998, 5:898-902.
20. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000, 7:693-699. 10.1038/78005, 10932256.
21. Lebeda FJ, Olson MA. Secondary structural predictions for the clostridial neurotoxins. Proteins: Struct Funct Gen 1994, 20:293-300.
22. Ginalski K, Venclovas C, Lesyng B, Fidelis K. Structure-based sequence alignment for the β-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Lett 2000, 482:119-124. 10.1016/S0014-5793(00)01954-2, 11018534.
23. Maddaloni M, Staats HF, Mierzejewska D, Hoyt T, Robison A, Callis G, Kozaki S, Kiyono H, McGhee JR, Fujihashi K, Pascual DW. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J Immunol 2006, 177:5524-5532.
24. Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther 2004, 10:616-629. 10.1016/j.ymthe.2004.07.013, 15451446.
25. Santosuosso M, McCormick S, Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005, 18:283-291. 10.1089/vim.2005.18.283, 16035940.
26. Boyer JL, Kobinger G, Wilson JM, Crystal RG. Adenovirus-based genetic vaccines for biodefense. Hum Gene Therapy 2005, 16:157-168.
27. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323. 10.1126/science.275.5304.1320, 9036860.
28. Josko D. Botulin toxin: a weapon in terrorism. Clin Lab Sci 2004, 17:30-34.
29. Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR. Recombinant holotoxoid vaccine against botulism. Infect Immun 2008, 76:437-442. 10.1128/IAI.00843-07, 2223665, 17967862.
30. Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, Pascual DW, Staats HF, Kiyono H, McGhee JR, Fujihashi K. A novel neurotoxoid vaccine prevents mucosal botulism. J Immunol 2005, 174:2190-2195.
31. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, Simpson LL. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007, 75:3043-3054. 10.1128/IAI.01893-06, 1932861, 17371853.
32. Boles J, West M, Montgomery V, Tammariello R, Pitt ML, Gibbs P, Smith L, LeClaire RD. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (Hc) immune response and protection in the rhesus monkey. Toxicon 2006, 47:877-884. 10.1016/j.toxicon.2006.02.013, 16730042.
33. Goyal AK, Khatri K, Mishra N, Vyas SP. New patents on mucosal delivery of vaccines. Expert Opin Ther Pat 2008, 18:1271-1288.
34. Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995, 63:2738-2742. 173366, 7790092.
35. Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA, Fritz RB, Johnson EA, Barbieri JT. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 2005, 73:6998-7005. 10.1128/IAI.73.10.6998-7005.2005, 1230911, 16177380.
36. Dertzbaugh MT, West MW. Mapping of protective and crossreactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 1996, 14:1538-1544. 10.1016/S0264-410X(96)00094-1, 9014296.
37. Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 2009, 16:367-375. 10.1038/gt.2008.181, 19129860.
38. Boyer JL, Kobinger G, Wilson JM, Crystal RG. Adenovirus-based genetic vaccines for biodefense. Hum Gene Therapy 2005, 16:157-168.
39. Muralidhar G, Navaratnam M, Englund N, Hariharan M, Sauer SL. Development of an adenoviral-based vaccine for HIV/AIDS. Cellscience Rev 2005, 2:1-15.
40. Soudais C, Laplace-Builhe C, Kissa K, Kremer EJ. Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J 2001, 12:2283-2285.
41. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochem Biophys Acta 2002, 1575:1-14.
42. Csencsitis KL, Pascual DW. Absence of L-selectin delays mucosal B cell responses in non-intestinal effector tissues. J Immunol 2002, 169:5649-5659.